NEW DELHI : Sakar Healthcare Limited share price rose over 11 per cent on September 1, 2026, hitting a fresh all-time high of Rs 999.00. The stock opened at Rs 866.30 against its previous close of Rs 863.35.
At the day’s high, it was up 15.72 per cent.
The rally followed the company’s update on multiple regulatory approvals across key overseas markets.
Multiple Approvals Across EU and UK Accord has received approvals for five additional product site variations from the European Medicines Agency (EMA), taking the total to six out of eight technology transfers initiated with Sakar Healthcare Limited.
Two other partners, based in the UK and Germany, have also secured approvals for three products from the Medicines and Healthcare products Regulatory Agency (MHRA) and EMA.
Separately, six of Sakar Healthcare Limited’s licensed-out products have received marketing authorisations.
Four are approved in the European Union, while one each has received approval in the UK and Canada.
Oncology Portfolio Expands
The approvals strengthen the company’s oncology portfolio, covering multiple cancer categories, including breast, lung, prostate, stomach, head and neck, colon and rectum, ovary, liver, kidney and thyroid cancers, along with blood, bone marrow and lymph-related cancers.
The company said the progress in regulated markets will help it leverage both its business models and support top-line growth.
About Sakar Healthcare Limited
Sakar Healthcare Limited has evolved from a contract manufacturer into an API-integrated pharmaceutical company with capabilities across oral solids, injectables and oncology formulations.
